ALCAM and colorectal cancer: Weichert et al (2004) described increased expression of CD166 from normal to tumour tissue, and, in a group of 111 colorectal cancer cases, observed correlation between membranous, but not cytoplasmic, CD166 expression and shortened survival. Patel et al (2009) also found a significant increase in CD166 expression in adenomatous glands and an age-dependent increase in CD44s and CD166 expression, correlating further with the number of polyps.